Skip to main content
Basilea Pharmaceutica AG logo

Basilea Pharmaceutica AG — Investor Relations & Filings

Ticker · BSLN ISIN · CH0011432447 LEI · 391200TTZP8EIPSJ5J20 SW Manufacturing
Open in API
Filings indexed 55 across all filing types
Latest filing 2025-07-08 Regulatory Filings
Country CH Switzerland
Listing SW BSLN

About Basilea Pharmaceutica AG

https://www.basilea.com/

Basilea Pharmaceutica is a commercial-stage biopharmaceutical company that develops and commercializes innovative pharmaceutical products. The company focuses on meeting the medical needs of patients with severe and life-threatening conditions, particularly bacterial and fungal infections. Its core activities revolve around its key anti-infective products, Cresemba and Zevtera, with a strategy to establish them as global brands. Basilea has a proven track record of advancing drugs from research and development through to market commercialization, aiming to become a leading company in the anti-infectives field.

Recent filings

Filing Released Lang Actions
Basilea erhält im Rahmen ihrer BARDA-Vereinbarung USD 39 Mio. für die weitere Entwicklung der neuen Antipilzmittel Fosmanogepix und BAL2062
Regulatory Filings Classification · 1% confidence The document is titled "Ad hoc-Mitteilung gemäss Art. 53 KR" (Ad hoc announcement according to Art. 53 KR) and is dated July 8, 2025. It announces that Basilea Pharmaceutica AG has received the next USD 39 million in funding from BARDA (Biomedical Advanced Research and Development Authority) under an existing 'Other Transaction Agreement' (OTA) to advance the development of its antifungal drug candidates. This is a specific, material, non-scheduled announcement concerning financing/funding related to R&D milestones. This fits best under 'Capital/Financing Update' (CAP) as it details the receipt of significant non-equity funding and milestones achieved under an agreement, which is a form of financing activity. It is not a full financial report (10-K or IR), an earnings release (ER), or a general regulatory filing (RNS), as it pertains specifically to a financing/development agreement milestone.
2025-07-08 German
Basilea reports strong 2024 full-year results with significant increase in revenue, profit and operating cash flow
Earnings Release Classification · 1% confidence The document is explicitly titled an "Ad hoc announcement pursuant to Art. 53 LR" and details the company's financial results for the full year ended December 31, 2024, including key metrics like revenue, operating profit, and net profit, along with future financial guidance for FY 2025. This content structure—a summary of period results, management commentary, and financial tables—is characteristic of an Earnings Release (ER). Although it contains comprehensive financial data, it is presented as an initial announcement (ad hoc) rather than the full, audited Annual Report (10-K) or a detailed Interim Report (IR). The presence of board nominations (MANG/CGR overlap) and a conference call announcement are common accompaniments to an ER. Therefore, ER is the most appropriate classification. FY 2024
2025-02-18 English
Basilea meldet für das Gesamtjahr 2024 ein starkes Ergebnis mit deutlichem Anstieg von Umsatz, Gewinn und operativem Cashflow
Earnings Release Classification · 1% confidence The document is titled "Ad hoc-Mitteilung gemäss Art. 53 KR" (Ad hoc announcement according to Art. 53 KR) and explicitly states that it publishes the 'Finanzergebnisse für das am 31. Dezember 2024 beendete Geschäftsjahr' (Financial results for the fiscal year ended December 31, 2024). It contains detailed financial summaries, key performance indicators for the full year, and financial outlook (Guidance) for 2025. This content strongly indicates a comprehensive release of annual financial performance, which aligns with the definition of an Annual Report (10-K) or, given the context of a Swiss ad-hoc release summarizing the full year, often serves as the primary communication for annual results, which is closely related to the 10-K function, but more specifically, it is a comprehensive report for a full year. However, since the text is an *announcement* summarizing the results and mentioning the full report is available online, and it contains management commentary and guidance, it fits best as a comprehensive report or an Earnings Release (ER) if it were quarterly. Since it covers the full fiscal year and provides detailed financial tables, it is more substantial than a typical ER. In the context of the provided definitions, a comprehensive report covering a full year's performance is best classified as an Annual Report (10-K) if it were the official filing, or an Earnings Release (ER) if it's the initial summary. Given the depth of financial data and the full-year scope, it functions as the primary annual results disclosure. Since it's an 'Ad hoc-Mitteilung' announcing the full-year results, it is functionally equivalent to the core content of an Annual Report disclosure, but often these initial comprehensive releases are classified as Earnings Releases (ER) if they precede the formal 10-K filing, or if they are the primary document released by non-US companies summarizing the year. Because it details the full year's results, profit, cash flow, and includes a forward-looking guidance section, it is a comprehensive financial results disclosure. The presence of detailed financial tables and full-year review points away from a simple 'Report Publication Announcement' (RPA). It is a detailed release of annual financial results, making 'ER' (Earnings Release, often used for comprehensive results announcements) or '10-K' (Annual Report) candidates. Given the structure and the fact it's a full-year summary, I will classify it as an Earnings Release (ER) as it is an immediate announcement of results, even though it covers the full year, which is often the function of the ER category when the document is not the formal 10-K filing itself. Furthermore, it includes governance updates (Board nominations), which sometimes appear in annual reports but are often included in comprehensive result releases. The core function is reporting the full-year financial outcome. I will select ER as the most appropriate fit for a comprehensive, immediate financial results announcement covering the full year, as 10-K is typically reserved for the specific SEC form. FY 2024
2025-02-18 German
Annual Report 2024
Annual Report Classification · 1% confidence The document is explicitly titled 'Annual Report 2024' and contains comprehensive sections including a letter to shareholders, business model, ESG commitment, corporate governance report, compensation report, and financial report sections. It covers the full fiscal year 2024 and provides detailed operational and financial performance data, fitting the definition of a 10-K (Annual Report). FY 2024
2025-02-13 English
Basilea is awarded additional CARB-X funding to develop new drug candidate from a novel class of antibiotics
Regulatory Filings Classification · 1% confidence The document is titled "Ad hoc announcement pursuant to Art. 53 LR" and is dated December 23, 2024. It details specific operational news (receiving additional funding for drug development) and concludes with a link to download the 'Press release (PDF)' and a general statement that the announcement can be downloaded from the company website. This structure—a brief announcement summarizing key news and pointing to the full document—is characteristic of a regulatory filing or press release that is not the comprehensive financial report itself (like 10-K or IR). Since it is an immediate, material announcement required by listing rules (Art. 53 LR), and it doesn't fit the specific categories like Director's Dealing (DIRS), Dividend (DIV), or Capital Change (CAP), the most appropriate general regulatory category is Regulatory Filings (RNS), which serves as a catch-all for immediate, non-standard announcements.
2024-12-23 English
Basilea erhält zusätzliche CARB-X-Förderung für die Entwicklung eines Medikamentenkandidaten einer neuen Antibiotika-Wirkstoffklasse
Regulatory Filings Classification · 1% confidence The document is explicitly titled "Ad hoc-Mitteilung gemäss Art. 53 KR" (Ad hoc announcement according to Art. 53 KR) and announces a specific, material event: receiving additional funding (USD 7.3 Mio.) from CARB-X to support the development of an antibiotic candidate (BAL2420). This type of immediate, material disclosure by a listed company (Basilea Pharmaceutica AG, SIX: BSLN) falls under the category of a general regulatory announcement that is not a standard periodic report (like 10-K or IR) or a specific financial event like a dividend or capital change. Since it is a material, unscheduled announcement, it best fits the general 'Regulatory Filings' category (RNS) as a catch-all for important, non-standard disclosures, or potentially an Earnings Release (ER) if it were tied to quarterly results, but here it is a specific funding/development milestone announcement. Given the options, RNS is the most appropriate fallback for an Ad hoc announcement not covered elsewhere. It is not a Call Transcript (CT), Earnings Release (ER) (as it's not reporting core financial results), or a Capital/Financing Update (CAP) (as it's grant funding, not a primary financing activity like issuing shares or debt). Therefore, RNS is selected.
2024-12-23 German

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.